Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models

Targeting the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway with immunotherapy has revolutionized the treatment of many cancers. Somatic tumor mutational burden (TMB) and T-cell–inflamed gene expression profile (GEP) are clinically validated pan-tumor genomic biomarkers that can...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiev, Peter, Muise, Eric S., Linn, Douglas E., Hinton, Marlene C., Wang, Yun, Cai, Mingmei, Cadzow, Louise, Wilson, Douglas C., Sukumar, Selvakumar, Caniga, Michael, Chen, Lan, Xiao, Hui, Yearley, Jennifer H., Sriram, Venkataraman, Nebozhyn, Michael, Sathe, Manjiri, Blumenschein, Wendy M., Kerr, Kimberly S., Hirsch, Heather A., Javaid, Sarah, Olow, Aleksandra K., Moy, Lily Y., Chiang, Derek Y., Loboda, Andrey, Cristescu, Razvan, Sadekova, Svetlana, Long, Brian J., McClanahan, Terrill K., Pinheiro, Elaine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377732/
https://www.ncbi.nlm.nih.gov/pubmed/34965960
http://dx.doi.org/10.1158/1535-7163.MCT-21-0561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377732/
https://www.ncbi.nlm.nih.gov/pubmed/34965960
http://dx.doi.org/10.1158/1535-7163.MCT-21-0561

Ejemplares similares